Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-765 dose-ranging study in treatment-resistant partial epilepsy
2011-004156-19Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Feb 2012
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of belnacasan in Focal Onset Epilepsy (3 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Percent reduction in weekly seizure frequency. Started Feb 2012; status: completed.
02
Drugs
belnacasan
03
Conditions
Focal Onset Epilepsy
Beyond the preview
Go deeper on 2011-004156-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004156-19.